- TRADE NAME: Recarbrio (MSD)
- INDICATIONS: Patients 18 years of age and older who have limited, or no alternative treatment options, for the treatment of the following infections caused by susceptible gram-negative bacteria: complicated urinary tract infections, including pyelonephritis; complicated intra-abdominal infections
- CLASS: Antibiotic, Antibiotic; carbapenem (imipenem), Antimicrobial, Beta-lactamase inhibitor (relebactam), Renal dehydropeptidase inhibitor (cilastatin)
- HALF-LIFE: 1 hour (imipenem); 1.2 hours (relebactam); 1 hour (cilastatin)
- FDA APPROVAL DATE: 07/16/2019
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
Ganciclovir, Valproic Acid - PREGNANCY: Insufficient human data to establish whether there is a drug-associated risk for major birth defects, miscarriage, or adverse maternal or fetal outcomes with imipenem, cilastatin, or relebactam in pregnant women.
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 08/20/2025
